| Sep 23 |
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal
|
| Sep 23 |
Ventyx stock climbs 8% on $27M Sanofi investment
|
| Sep 23 |
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
|
| Sep 6 |
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
|
| Aug 30 |
Ventyx Biosciences CFO departs
|
| Aug 30 |
Ventyx Biosciences Announces Departure of Chief Financial Officer
|
| Aug 30 |
Novo builds heart failure case for semaglutide; Ventyx CFO departs
|
| Aug 9 |
Ventyx Biosciences GAAP EPS of -$0.45
|
| Aug 8 |
Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
|
| Jul 30 |
Ventyx scraps TYK2 inhibitor after Phase II Crohn’s defeat
|
